Biomedical leaders hope they'll be able to find bipartisan support to stall or repeal a 2.3% excise tax on all medical devices sold in the United States before it comes back online on Jan. 1, 2018.
Three former Republican- and Democrat-appointed HHS chiefs have four words of advice for President Donald Trump and the GOP-led Congress as Obamacare seems here for the foreseeable future: Don't make things worse.
The changing role of healthcare is putting CEOs in the spotlight more often, sometimes requiring them to take action.
Single-payer is likely a long way off in the U.S., but progressives want to talk about how it could be done.
President Donald Trump says he's ending a pair of White House advisory councils that were staffed by corporate chief executives. Merck and Johnson & Johnson are among the parade of departing leaders from the informal panel.
The CBO says that ending CSR payments to insurers would cost the federal government more than continuing to pay them, because insurers would hike premiums, and subsidies would then rise as well.
The group urged Congress to take bipartisan action by the end of September to stabilize the individual insurance market until a longer-term resolution can be achieved and to protect healthcare access and coverage.
A sizable number of Americans eligible for premium subsidies are passing them up by buying health insurance outside the Affordable Care Act's insurance exchanges. That could be affecting the health of the individual insurance market, particularly to the extent people are buying plans that do not...
Despite resistance from some colleagues, Rep. Tom Reed (R-N.Y.) thinks a majority of Republicans in the House could sign onto an Obamacare fix.
More than two dozen risk-corridor lawsuits are pending in the federal court of claims, brought by insurers that were denied the payments. The federal court has split on the issue.
The new bipartisan effort to craft solutions is almost certain to run into the same battles over how to bring down premiums for healthy people without raising costs for older and sicker people.
The bill, which now awaits the president's approval, has received broad support from medical device and pharmaceutical groups as a means to add more certainty and efficiency to the product review process.